Member

There are two data printouts in 2023. Insiders and funds are beefing up their positions. Stay tuned!

There is no way nor any evidence that Mango works faster. Zero science. Zero proof. Someone keeps posting general drug descriptions for generic drugs as evidence. Is MANGO FDA approved? NO! SHOW EVIDENCE OF APPROVAL FOR MANGO. THERE IS NONE. Show any scientific study for MANGO product. There is zero. PLEASE STOP POSTING LINKS TO GENERIC DRUG DESCRIPTIONS.

That lay post is a lie. FDA never said that. Click on link takes you to mango website. I’m forwarding post to the FDA. Terrible. Your truth equity is zero.

Lot of social hype. No product. FDA??

Is this drug any different then Tadalafil? They attached or blended arginine to the drug. Any validated science? Is this FDA approved or just a compound pharmacy play? Sounds like a product i can buy online from anyone. Not sure what’s so unique about their mango.

Bert, Ernie called. He said buy more SYRS and watch your language.

$SYRS is stock for the wise, educated and less emotional. They have real science, excellent management, plenty of cash and two data printouts in 2023. The old Tyme shareholders had a lockup that ended this past week. They sold their positions to move on and explore new ventures. Once they sell, stock will recover and cruise to over 10 dollars a share in 2023.

$SYRS next inflection point will come with the data printout in Q2/Q3 of 2023. Big news on the horizon. SYROS is on the radar of big pharma.

$SYRS has two data printouts in 2023. Last data printout in 2022 was compelling. Insiders and funds are increasing ownership. Great buy at this price. Company is an excellent acquisition candidate. Analysts see two drugs being approved by 2024.

Hi Bert. Ernie called and said buy more shares of &SYRS. Former Tyme shareholder selling. His lockup ended a few days ago. Stock will recover.